Griseofulvin is an antibiotic derived from a species of Penicillium. Each 5 mL of Griseofulvin Oral Suspension, USP contains 125 mg of Griseofulvin (microsize) and also contains alcohol (0.2%), docusate sodium, FD&C Red No. 40, FD&C Yellow No. 6, magnesium aluminum silicate, menthol, methylparaben, orange cream flavors, propylene glycol, propylparaben, purified water, saccharin sodium, simethicone emulsion, sodium alginate and sucrose.
Clinical Pharmacology
Griseofulvin Oral Suspension, USP acts systemically to inhibit the growth of Trichophyton, Microsporum, and Epidermophyton genera of fungi. Fungistatic amounts are deposited in the keratin, which is gradually exfoliated and replaced by noninfected tissue.
Griseofulvin absorption from the gastrointestinal tract varies considerably among individuals, mainly because of insolubility of the drug in aqueous media of the upper G.I. tract. The peak serum level found in fasting adults given 0.5 gm occurs at about four hours and ranges between 0.5 and 2.0 mcg/mL.
It should be noted that some individuals are consistently “poor absorbers” and tend to attain lower blood levels at all times. This may explain unsatisfactory therapeutic results in some patients. Better blood levels can probably be attained in most patients if Griseofulvin is administered after a meal with a high fat content.
Indications and Usage
Major indications for Griseofulvin Oral Suspension, USP are:
Tinea capitis (ringworm of the scalp)
Tinea corporis (ringworm of the body)
Tinea pedis (athlete’s foot)
Tinea unguium (onychomycosis; ringworm of the nails)
Tinea cruris (ringworm of the thigh)
Tinea barbae (barber’s itch)
Griseofulvin Oral Suspension, USP inhibits the growth of those genera of fungi that commonly cause ringworm infections of the hair, skin, and nails, such as:
Trichophyton rubrum
Trichophyton tonsurans
Trichophyton mentagrophytes
Trichophyton interdigitalis
Trichophyton verrucosum
Trichophyton sulphureum
Trichophyton schoenleini
Microsporum audouini
Microsporum canis
Microsporum gypseum
Epidermophyton floccosum
Trichophyton megnini
Trichophyton gallinae
Trichophyton crateriform
Note: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical anti-fungal agents alone.
It is not effective in:
Bacterial infections
Candidiasis (Moniliasis)
Histoplasmosis
Actinomycosis
Sporotrichosis
Chromoblastomycosis
Coccidioidomycosis
North American Blastomycosis
Cryptococcosis (Torulosis)
Tinea versicolor
Nocardiosis
Contraindications
This drug is contraindicated in patients with porphyria, hepatocellular failure, and in individuals with a history of hypersensitivity to Griseofulvin.
Two cases of conjoined twins have been reported in patients taking Griseofulvin during the first trimester of pregnancy. Griseofulvin should not be prescribed to pregnant patients.
Warnings
Prophylactic Usage:
Safety and efficacy of prophylactic use of this drug has not been established.
Chronic feeding of Griseofulvin, at levels ranging from 0.5-2.5% of the diet, resulted in the development of liver tumors in several strains of mice, particularly in males. Smaller particle sizes result in an enhanced effect. Lower oral dosage levels have not been tested. Subcutaneous administration of relatively small doses of Griseofulvin once a week during the first three weeks of life has also been reported to induce hepatomata in mice. Although studies in other animal species have not yielded evidence of tumorigenicity, these studies were not of adequate design to form a basis for conclusions in this regard.
In subacute toxicity studies, orally administered Griseofulvin produced hepatocellular necrosis in mice, but this has not been seen in other species. Disturbances in porphyrin metabolism have been reported in Griseofulvin-treated laboratory animals. Griseofulvin has been reported to have a colchicine-like effect on mitosis and cocarcinogenicity with methylcholanthrene in cutaneous tumor induction in laboratory animals.
Reports of animal studies in the Soviet literature state that a Griseofulvin preparation was found to be embryotoxic and teratogenic on oral administration to pregnant Wistar rats. Rat reproduction studies done in the United States and Great Britain were inconclusive in this regard. Pups with abnormalities have been reported in the litters of a few bitches treated with Griseofulvin. Because the potential for adverse effects on the human fetus cannot be ruled out, additional contraceptive precautions should be taken during treatment with Griseofulvin and for a month after termination of treatment. Griseofulvin Oral Suspension, USP should not be prescribed to women intending to become pregnant within one month following cessation of therapy.
Suppression of spermatogenesis has been reported to occur in rats but investigation in man failed to confirm this. Griseofulvin interferes with chromosomal distribution during cell division, causing aneuploidy in plant and mammalian cells. These effects have been demonstrated in vitro at concentrations that may be achieved in the serum with the recommended therapeutic dosage.
Since Griseofulvin has demonstrated harmful effects in vitro on the genotype in bacteria, plants, and fungi, males should wait at least six months after completing Griseofulvin therapy before fathering a child.
Precautions
Patients on prolonged therapy with any potent medication should be under close observation. Periodic monitoring of organ system function, including renal, hepatic and hemopoietic, should be done.
Since Griseofulvin is derived from species of penicillin, the possibility of cross sensitivity with penicillin exists; however, known penicillin-sensitive patients have been treated without difficulty.
Since a photosensitivity reaction is occasionally associated with Griseofulvin therapy, patients should be warned to avoid exposure to intense natural or artificial sunlight. Should a photosensitivity reaction occur, lupus erythematosus may be aggravated.
Drug Interactions:
Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after Griseofulvin therapy. Concomitant use of barbiturates usually depresses Griseofulvin activity and may necessitate raising the dosage.
The concomitant administration of Griseofulvin has been reported to reduce the efficacy of oral contraceptives and to increase the incidence of breakthrough bleeding.
Adverse Reactions
When adverse reactions occur, they are most commonly of the hypersensitivity type such as skin rashes, urticaria and rarely, angioneurotic edema or erythema multiforme-like drug reaction, and may necessitate withdrawal of therapy and appropriate countermeasures. Paresthesias of the hands and feet have been reported rarely after extended therapy. Other side effects reported occasionally are oral thrush, nausea, vomiting, epigastric distress, diarrhea, headache, fatigue, dizziness, insomnia, mental confusion and impairment of performance of routine activities.
Proteinuria and leukopenia have been reported rarely. Administration of the drug should be discontinued if granulocytopenia occurs.
When rare, serious reactions occur with Griseofulvin, they are usually associated with high dosages, long periods of therapy, or both.
Dosage and Administration
Accurate diagnosis of the infecting organism is essential. Identification should be made either by direct microscopic examination of a mounting of infected tissue in a solution of potassium hydroxide or by culture on an appropriate medium.
Medication must be continued until the infecting organism is completely eradicated as indicated by appropriate clinical or laboratory examination. Representative treatment periods are tinea capitis, 4 to 6 weeks; tinea corporis, 2 to 4 weeks; tinea pedis, 4 to 8 weeks; tinea unguium - depending on rate of growth - fingernails, at least 4 months; toenails, at least 6 months.
General measures in regard to hygiene should be observed to control sources of infection or reinfection. Concomitant use of appropriate topical agents is usually required, particularly in treatment of tinea pedis since in some forms of athlete’s foot, yeasts and bacteria may be involved. Griseofulvin will not eradicate the bacterial or monilial infection.
Adults:
A daily dose of 500 mg will give a satisfactory response in most patients with tinea corporis, tinea cruris, and tinea capitis.
For those fungus infections more difficult to eradicate such as tinea pedis and tinea unguium, a daily dose of 1 gram is recommended.
Children:
Approximately 5 mg per pound of body weight per day is an effective dose for most children. On this basis the following dosage schedule for children is suggested:
Children weighing 30 to 50 pounds - 125 mg to 250 mg daily.
Children weighing over 50 pounds - 250 mg to 500 mg daily.
How Supplied
Griseofulvin Oral Suspension, USP (microsize) 125 mg per 5 mL is available as follows:
4 fl oz (120 mL) bottle (NDC 45802-968-26)
Dispense Griseofulvin Oral Suspension, USP in a tight, light-resistant container as defined in the USP.
Storage
Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].
Made in Israel
Manufactured by Perrigo
Yeruham 80500, Israel
Distributed by Perrigo
Allegan, MI 49010
www.perrigo.com
Rev. 01/11
Principal Display Panel - Top Label
Peel Here
Griseofulvin Oral Suspension, USP
(microsize) 125 mg/5mL
Each 5 mL (one teaspoonful) contains 125 mg Griseofulvin microsize in a palatable suspension, colored orange.
Also contains alcohol 0.2%.
Rx Only
Griseofulvin Oral Suspension, USP Top Label
Principal Display Panel - Bottom Label
Griseofulvin Oral Suspension, USP
(microsize) 125 mg/5mL
Each 5 mL (one teaspoonful) contains 125 mg Griseofulvin microsize in a palatable suspension, colored orange.
Also contains alcohol 0.2%.
Rx Only
Close Tightly
Griseofulvin Oral Suspension, USP Bottom Label
| Griseofulvin Griseofulvin suspension | ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| ANDA | ANDA065200 | 07/16/2008 | |
| Labeler - Perrigo New York Inc (078846912) |
More Griseofulvin resources
- Griseofulvin Side Effects (in more detail)
- Griseofulvin Dosage
- Griseofulvin Use in Pregnancy & Breastfeeding
- Drug Images
- Griseofulvin Drug Interactions
- Griseofulvin Support Group
- 5 Reviews for Griseofulvin - Add your own review/rating
- Griseofulvin Professional Patient Advice (Wolters Kluwer)
- Griseofulvin Monograph (AHFS DI)
- Griseofulvin Microsize Oral Suspension MedFacts Consumer Leaflet (Wolters Kluwer)
- griseofulvin Advanced Consumer (Micromedex) - Includes Dosage Information
- griseofulvin Concise Consumer Information (Cerner Multum)
- Gris-PEG Ultramicrosize Tablets MedFacts Consumer Leaflet (Wolters Kluwer)
- Grisactin 250 Concise Consumer Information (Cerner Multum)
Compare Griseofulvin with other medications
- Dermatophytosis
- Onychomycosis, Fingernail
- Onychomycosis, Toenail
- Tinea Barbae
- Tinea Capitis
- Tinea Corporis
- Tinea Cruris
- Tinea Pedis
No comments:
Post a Comment